The incidence of Drug-Induced Liver Injury (DILI) is a growing challenge because of the ever-increasing number of drugs used in medical care. This webinar brings together leading DILI experts from regulatory authorities, the pharmaceutical industry and academia as they introduce the consensus report of the Council for International Organizations of Medical Sciences (CIOMS) DILI Working Group. The report provides a critical framework and essential tools to detect, diagnose and manage DILI during drug development and post-marketing. 

The webinar welcomes professionals from the pharmaceutical industry, including investigators who capture, analyze and communicate liver safety data in drug development, regulators who evaluate new products and/or emerging DILI biomarkers, and health care providers who monitor and manage patients treated with potentially hepatotoxic drugs.